---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-004414"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2022-02-09T23:59:59+00:00"
generated_at: "2026-06-27T09:39:48.947266+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Galecto forms R&D Committee, boosts non-executive Chair option grant to 36,000 shares

## Summary
- R&D Committee established; members receive $7,500/yr retainer, Chair gets additional $7,500/yr.
- Non-Executive Chair annual option grant increased from 18,000 to 36,000 shares; other directors remain at 18,000.
- Initial equity award of 18,000 options vests over 36 months; annual award vests over 12 months.

## SEC filing metadata
- accession: 0001564590-22-004414
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2022-02-09T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000156459022004414/0001564590-22-004414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000156459022004414/glto-8k_20220203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-004414
- JSON: https://secwatch.observer/filing/0001564590-22-004414.json
- Plain text: https://secwatch.observer/filing/0001564590-22-004414.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.